ArticleHand (New York, N.Y.)2026
Trends in Thumb Carpometacarpal Arthroplasty: A Decade in Review.
Article in Hand (New York, N.Y.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCarpometacarpal (CMC) arthroplasty can provide symptomatic relief and improvement in function in patients with CMC osteoarthritis. The study purpose was to identify demographic, 30-day outcome, and reimbursement trends in CMC arthroplasty between 2012 and 2021.
methodsThis was a retrospective cohort study of adult patients undergoing CMC arthroplasty from January 1, 2012, to December 31, 2021, using the National Surgical Quality Improvement Program database. Patients were stratified based on year of index surgery: 2012-2015, 2016-2018, and 2019-2021. Baseline characteristics were collected and compared using the appropriate statistical test. Multivariable logistic regressions controlling for age and sex were performed to identify independent risk factors for 30-day morbidity, readmissions, and reoperations. Economic analyses assessed changes in reimbursement rates over the span of 10 years.
resultsA total of 9046 patients were included in the analysis with mean age of 62.7 ± 9.2 and women comprising 74.9% of the total population. Between 2012 and 2021, the annual volume increased from 433 to 1043. The average body mass index (BMI) and proportion of patients with congestive heart failure (CHF) increased in 2019-2021. Increasing age, BMI, smoking, and length of stay ≥ 1 day were independent risk factors for 30-day readmissions. The Medicare reimbursement fee decreased by an average of 1.15% annually, for a total of 9.90% across 10 years.
conclusionsThe volume of CMC arthroplasty has risen from 2012 to 2021. However, conditions such as obesity and CHF have become more prevalent. Despite the growing patient complexity, Medicare reimbursement fees have markedly decreased.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.